New <em>in vitro</em> interaction-parasite reduction ratio assay for early derisk in clinical development of antimalarial combinations (Publications)
The development and spread of drug-resistant phenotypes substantially threaten malaria control efforts. Combination therapies have the potential to minimize the risk of resistance development but require [...] will significantly improve and streamline the economic development of new drug combinations for malaria and potentially also in other therapeutic areas.
Efficacy and safety of moxidectin, synriam, synriam-praziquantel <em>versus</em> praziquantel against <em>Schistosoma haematobium</em> and <em>S.... (Publications)
analysis or three urine samples (S. haematobium trial) for urine filtration and one finger prick for malaria screening at baseline and follow-up. Participants were randomly assigned to either moxidectin, Synriam [...] hence an ancillary benefit is not expected when these drugs are used for treating onchocerciasis and malaria in co-endemic settings. Further studies are needed to corroborate our findings that moxidectin and
Changes in metabolic phenotypes of <em>Plasmodium falciparum</em> <em>in vitro</em> cultures during gametocyte development (Publications)
s are the Plasmodium life stage that is solely responsible for malaria transmission. Despite their important role in perpetuating malaria, gametocyte differentiation and development is poorly understood
Activation of TCR Vδ1+ and Vδ1-Vδ2- γδ T cells upon controlled infection with <em>Plasmodium falciparum</em> in Tanzanian volunteers (Publications)
immune response to malaria remains incomplete. Clinical trials using whole-sporozoite-based vaccination approaches such as the Sanaria PfSPZ Vaccine, followed by controlled human malaria infection (CHMI)
Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against<em> Plasmodium falciparum</em> parasites in... (Publications)
emerged as a promising blood-stage candidate antigen for inclusion into a broadly cross-reactive malaria vaccine. This highly conserved protein among various geographical strains plays a key role in the [...] falciparum merozoites, and antibodies against PfCyRPA can efficiently prevent the entry of the malaria parasites into red blood cells. The aim of the present study was to develop a humancompatible formulation
Clinical trials in low-resource settings: the perspectives of caregivers of paediatric participants from Uganda, Tanzania and Kenya (Publications)
study investigates the experience of caregivers consenting on behalf of paediatric participants in a malaria vaccine clinical trial where participation enables access to free, high-quality medical care. METHODS: [...] interviewed a total of 78 caregivers of paediatric participants previously enrolled in a phase II or III malaria vaccine clinical trial in Uganda, Tanzania and Kenya. Interviews were qualitative and analysed using
Detection of <em>Plasmodium falciparum</em> infected <em>Anopheles gambiae</em> using near‑infrared spectroscopy (Publications)
demonstrates proof-of-concept that NIRS is capable of rapidly identifying laboratory strains of human malaria infection in African mosquito vectors. CONCLUSIONS: Accurate, low-cost, reagent-free screening of [...] by NIRS could revolutionize surveillance and elimination strategies for the most important human malaria parasite in its primary African vector species. Further research is needed to evaluate how the method
Parasite-host dynamics throughout antimalarial drug development stages complicate the translation of parasite clearance (Publications)
Ensuring continued success against malaria depends on a pipeline of new antimalarials. Antimalarial drug development utilizes pre-clinical murine and experimental human malaria infection studies to evaluate
Inhibitors of Plasmepsin II-potential antimalarial agents (Publications)
In order to overcome the problem of drug resistance in malaria, it appears wise to concentrate drug discovery efforts toward new structural classes and new mechanisms of action. We report our results,
Inhibitors of Plasmepsin II-potential antimalarial agents (Publications)
In order to overcome the problem of drug resistance in malaria, it appears wise to concentrate drug discovery efforts toward new structural classes and new mechanisms of action. We report our results,